var data={"title":"Telavancin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Telavancin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/394830?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=telavancin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Telavancin: Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11238847\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Moderate to severe renal impairment:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Patients with preexisting moderate to severe renal impairment (creatinine clearance [CrCl] 50 mL/minute or less) who were treated with telavancin for hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia had increased mortality observed versus vancomycin. Consider use of telavancin in patients with preexisting moderate to severe renal impairment (CrCl 50 mL/minute or less) only when the anticipated benefit to the patient outweighs the potential risk.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Nephrotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">New-onset or worsening renal impairment has occurred. Monitor renal function in all patients.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Fetal risk:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Women of childbearing potential should have a serum pregnancy test prior to administration. Avoid use during pregnancy unless the potential benefit to the patient outweighs the potential risk to the fetus. Adverse developmental outcomes observed in 3 animal species at clinically relevant doses raise concerns about potential adverse developmental outcomes in humans.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8119746\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Vibativ</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8308550\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Glycopeptide</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9739342\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Complicated skin and skin structure infection:</b> IV: 10 mg/kg every 24 hours for 1 to 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP):</b> IV: 10 mg/kg every 24 hours for 1 to 3 weeks</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9739346\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9739343\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Renal function may be estimated using the Cockcroft-Gault formula for dosage adjustment purposes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 50 mL/minute: 7.5 mg/kg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 10 to &lt;30 mL/minute: 10 mg/kg every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;10 mL/minute: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ESRD and hemodialysis patients: No dosage adjustment provided in manufacturer&rsquo;s labeling  (has not been studied). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 50 mL/minute: 7.5 mg/kg every 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute: Not recommended. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ESRD and hemodialysis patients: Not recommended. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9739344\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild-to-moderate hepatic impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe hepatic impairment (Child-Pugh class C): No dosage adjustment provided in manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9739353\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vibativ: 250 mg (1 ea [DSC]); 750 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9739185\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9739184\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM183838.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+nIf162NgDrXSMpjxmnBPQB+vX7daHTImzlcLxwLor0A==&amp;TOPIC_ID=9535\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM183838.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9739348\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer IV over 60 minutes. Other medications should not be infused simultaneously through the same IV line. When the same intravenous line is used for sequential infusion of other medications, flush line with D<sub>5</sub>W, LR, or NS before and after infusing telavancin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Red-man syndrome may occur if the infusion is too rapid. It is not an allergic reaction, but may be characterized by hypotension and/or a maculopapular rash appearing on the face, neck, trunk, and/or upper extremities. If this should occur, discontinuing or slowing the infusion rate may eliminate these reactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8308551\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Complicated skin and skin structure infections: Treatment of complicated skin and skin structure infections caused by susceptible gram-positive organisms including methicillin-susceptible or -resistant <i>Staphylococcus aureus</i>, vancomycin-susceptible <i>Enterococcus faecalis</i>, and <i>Streptococcus pyogenes</i>, <i>Streptococcus agalactiae</i>, or <i>Streptococcus anginosus</i>  group</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP): Treatment of HABP/VABP caused by susceptible isolates of <i>Staphylococcus aureus</i> when alternative treatments are not appropriate</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8308548\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Telavancin may be confused with telithromycin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vibativ may be confused with Viactiv, Vibramycin, vigabatrin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9739198\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Metallic taste (33%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (5% to 27%), vomiting (5% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (8% to 16%; &ge;65 years of age: 11%; &lt;65 years of age: 8%), foamy urine (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (6%), infusion site pain (4%), rigors (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (3% to 6%), skin rash (4%), localized erythema (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (7%), decreased appetite (3%), abdominal pain (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Infusion site reaction (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal insufficiency (3%; &ge;65 years of age: 9%; &lt;65 years of age: 2%), acute renal failure (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: <i>Clostridium difficile</i> associated diarrhea, flushing, hypersensitivity reaction (including anaphylaxis), nephrotoxicity, prolonged Q-T interval on ECG, transient flushing of upper body, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9739191\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to telavancin or any component of the formulation; concomitant use of intravenous unfractionated heparin</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9739192\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis/hypersensitivity reactions: Serious hypersensitivity reactions, including anaphylaxis, have been reported after first or subsequent doses; some have been fatal. Discontinue if hypersensitivity or rash occurs. Telavancin is a semisynthetic derivative of vancomycin; cross-reactivity rates are unknown. Use with caution in patients with known vancomycin hypersensitivity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac conduction alteration: May prolong QTc interval; avoid use in patients with congenital long QT syndrome, known QTc prolongation, uncompensated heart failure, or severe left ventricular hypertrophy (were excluded from studies); use with caution in patients with concurrent administration of other medications known to prolong the QT interval. Clinical studies indicate mean maximal QTc prolongation of 12 to 15 msec at the end of 10 mg/kg infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Rapid IV administration may result in flushing, rash, urticaria, and/or pruritus; slowing or stopping the infusion may alleviate these symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotoxicity: <b>[US Boxed Warning]: New onset or worsening renal impairment has occurred. Monitor renal function prior to, during (at least every 48 to 72 hours; more frequently if indicated), and following therapy in all patients.</b> Usual risk factors include concomitant nephrotoxic medications or baseline comorbidities associated with decreased renal function (eg baseline renal dysfunction, diabetes, hypertension, or heart failure). Contains solubilizer cyclodextrin (hydroxypropyl-beta-cyclodextrin) which may accumulate in patients with renal dysfunction, although the clinical significance of this finding is uncertain (Luke, 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: <b>[US Boxed Warning]: In clinical studies, patients with pre-existing moderate-to-severe renal impairment (CrCl &le;50 mL/minute) treated for hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) had increased (all cause) mortality versus vancomycin. Use in HABP/VABP only when benefit outweighs risk.</b> In patients with complicated skin and skin structure infections, efficacy may be reduced in patients with a baseline CrCl &le;50 mL/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Lower doses are often required secondary to age-related decreases in renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: <b>[US Boxed Warning]: Based on animal data, adverse developmental outcomes have been observed. Prior to use, women of childbearing potential should have a serum pregnancy test. Use of telavancin is not recommended during pregnancy unless the potential benefit outweighs the risk to the fetus.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Coagulation tests: May interfere with tests used to monitor coagulation (eg, prothrombin time, INR, activated partial thromboplastin time, activated clotting time, coagulation based factor Xa tests) when samples drawn &le;18 hours after drug administration. Blood samples should be collected as close to the next dose of telavancin as possible or a non-phospholipid dependent coagulation test (eg, bleeding time, factor Xa [chromogenic assay], platelet aggregation study, thrombin time) should be used. Consider selecting an alternative anticoagulant not requiring aPTT monitoring; concomitant use of telavancin with IV unfractionated heparin is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300108\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9613187\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9535&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Telavancin may diminish the therapeutic effect of Anticoagulants. Specifically, telavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses. <b> Exceptions: </b>Antithrombin; Bemiparin; Dalteparin; Enoxaparin; Fondaparinux; Nadroparin; Protein C Concentrate (Human); Tinzaparin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparin: Telavancin may diminish the therapeutic effect of Heparin. Specifically, telavancin may artificially increase the results of laboratory tests commonly used to monitor IV heparin effectiveness, which could lead to incorrect decisions to decrease heparin doses. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9739187\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9739188\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>[US Boxed Warning]: Based on animal data, adverse developmental outcomes have been observed. Prior to use, women of childbearing potential should have a serum pregnancy test. Use of telavancin is not recommended during pregnancy unless the potential benefit to the mother outweighs the possible risk to the fetus.</b> Telavancin crosses the placenta (Nanovskaya, 2012). In women of childbearing potential, effective contraception should be used during therapy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Healthcare providers are encouraged to enroll women exposed to telavancin during pregnancy in the Vibativ Pregnancy Registry (855-633-8479).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14456864\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\"> The Canadian labeling recommends discontinuing breast-feeding during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">It is not known if telavancin is excreted in breast milk. The US labeling recommends that caution be exercised when administering telavancin to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9739351\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function (prior to start, every 48 to 72 hours; more frequently if indicated, and following therapy), pregnancy test</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9739219\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Exerts concentration-dependent bactericidal activity; inhibits bacterial cell wall synthesis by blocking polymerization and cross-linking of peptidoglycan by binding to D-Ala-D-Ala portion of cell wall. Unlike vancomycin, additional mechanism involves disruption of membrane potential and changes cell permeability due to presence of lipophilic side chain moiety.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9739293\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>ss</sub>: 0.13 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~90%; primarily to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 6.6-9.6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~76%); feces (&lt;1%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23613347\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Vibativ Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (1): $505.66</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23671491\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Vibativ (AT, BB, CZ, DE, DK, EE, ES, FI, GB, HR, HU, IE, LT, MT, NL, PL, PT, SE, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Liu C, Bayer A, Cosgrove SE, et al, &ldquo;Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant <i>Staphylococcus Aureus</i> Infections in Adults and Children: Executive Summary,&rdquo; <i>Clin Infect Dis</i>, 2011, 52(3):285-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/telavancin-drug-information/abstract-text/21217178/pubmed\" target=\"_blank\" id=\"21217178\">21217178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Luke DR, Tomaszewski K, Damle B, Schlamm HT. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). <i>J Pharm Sci</i>. 2010;99(8):3291-3301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/telavancin-drug-information/abstract-text/20213839/pubmed\" target=\"_blank\" id=\"20213839\">20213839</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nanovskaya T, Patrikeeva S, Zhan Y, et al, &quot;Transplacental Transfer of Vancomycin and Telavancin,&quot; <i>Am J Obstet Gynecol</i>, 2012, 207(4):331.e1-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/telavancin-drug-information/abstract-text/22867688/pubmed\" target=\"_blank\" id=\"22867688\">22867688</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubinstein E, Lalani T, Corey GR, et al, &ldquo;Telavancin versus Vancomycin for Hospital-Acquired Pneumonia Due to Gram-Positive Pathogens,&rdquo; <i>Clin Infect Dis</i>, 2011, 52(1):31-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/telavancin-drug-information/abstract-text/21148517/pubmed\" target=\"_blank\" id=\"21148517\">21148517</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/telavancin-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stryjewski ME, Chu VH, O&rsquo;Riordan WD, et al, &ldquo;Telavancin Versus Standard Therapy for Treatment of Complicated Skin and Skin-Structure Infections Caused by Gram-Positive Bacteria: Fast 2 Study,&rdquo; <i>Antimicrob Agents Chemother</i>, 2006, 50(3):862-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/telavancin-drug-information/abstract-text/16495243/pubmed\" target=\"_blank\" id=\"16495243\">16495243</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stryjewski ME, Graham DR, Wilson SE, et al, &ldquo;Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin-Structure Infections Caused by Gram-Positive Organisms,&rdquo; <i>Clin Infect Dis</i>, 2008, 46(11):1683-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/telavancin-drug-information/abstract-text/18444791/pubmed\" target=\"_blank\" id=\"18444791\">18444791</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stryjewski ME, O&rsquo;Riordan WD, Lau WK, et al, &ldquo;Telavancin Versus Standard Therapy for Treatment of Complicated Skin and Soft-Tissue Infections Due to Gram-Positive Bacteria,&rdquo; <i>Clin Infect Dis</i>, 2005, 40(11):1601-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/telavancin-drug-information/abstract-text/15889357/pubmed\" target=\"_blank\" id=\"15889357\">15889357</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <i>Vibativ</i> (telavancin) [prescribing inforamtion]. South San Francisco, CA: Theravance Inc; November 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vibativ (telavancin) [product monograph]. Montreal, Quebec, Canada: Pendopharm, Division of Pharmascience Inc; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilson SE, O&rsquo;Riordan W, Hopkins A, et al, &ldquo;Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin-Structure Infections Associated With Surgical Procedures,&rdquo; <i>Am J Surg</i>, 2009, 197(6):791-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/telavancin-drug-information/abstract-text/19095213/pubmed\" target=\"_blank\" id=\"19095213\">19095213</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9535 Version 144.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F11238847\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8119746\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F8308550\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F9739342\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F9739346\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F9739343\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F9739344\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9739353\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F9739185\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F9739184\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9739348\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F8308551\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8308548\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9739198\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9739191\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9739192\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300108\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9613187\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F9739187\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9739188\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F14456864\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F9739351\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9739219\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F9739293\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F23613347\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23671491\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9535|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=telavancin-patient-drug-information\" class=\"drug drug_patient\">Telavancin: Patient drug information \t</a></li></ul></div></div>","javascript":null}